Cytotoxicity and adjuvant activity of cationic photosensitizers in a multidrug resistant cell line

Journal of Chemotherapy

Volumn 11, Issue 1, 1999, Pages 61-68

  Wainwright, M ^a   Phoenix, D A ^a   Burrow, S M ^a   Waring, J ^a  

^a UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

MDR; Methylene blue; Multidrug resistance; Photosensitizers; Toluidine blue; Victoria blue BO

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARDIOLIPIN; CISPLATIN; DOXORUBICIN; GLYCOPROTEIN P; METHYLENE BLUE; PHOTOSENSITIZING AGENT; TOLONIUM CHLORIDE; UNCLASSIFIED DRUG; VERAPAMIL; VICTORIA BLUE BO;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; STRUCTURE ACTIVITY RELATION;

EID: 0032970489     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.1.61     Document Type: Article

References (37)

1. 1 Gotesman MM, Pastan I. Resistance to multiple chemotherapeutic agents in human cancer cells. Trends Pharm Sci 1988; 9: 54-91.
2. 2 Kartner N, Ling V. Multidrug resistance in cancer. Scientific American 1989; 260: 29-33.
3. 3 Juranka PF, Zastawny RL, Ling V. P-glycoprotein: multidrug resistance and a superfamily of membrane-associated transport proteins. FASEB J 1989; 3: 2583-2592.
4. 4 Clynes M. Cellular models for multidrug resistance in cancer. In vitro. Cell Dev Biol. 1993; 29A: 171-179.
5. 5 Twentyman PR. Non-P-glycoprotein mediated MDR. Cancer Topics 1993; 9: 46-47.
6. 6 von Schweinitz D, Byrd DJ, Hecker H et al. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Eur J Cancer 1997; 33: 1243-1249.
7. 7 Bower M, Newlands ES, Holden L et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol 1997; 15: 2636-2643.
8. 8 Henderson B, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992; 55: 145-157.
9. 9 Foote CS. Chemical mechanisms of photodynamic action. SPIE 1990; 6: 115-126.
10. 10 Montforts FP, Meier A, Scheurich G, Haake G, Bats J. Chlorins designed for photodynamic tumour therapy and as model systems for photosynthesis. Angew Chem Int Ed 1992; 31: 1592-1594.
11. 11 Boyle RW, Leznoff CC van Lier JE. Biological activities of phthalocyanines-XVI. Tetrahydroxy-and tetraalkylhydroxy zinc phthalocyanines. Effect of alkyl chain length on in vitro and in vivo photodynamic activites. Br J Cancer 1993; 67: 1177-1181.
12. 12 Wainwright M, Phoenix DA, Rice L, Burrow SM, Waring J. Increased cytotoxicity and phototoxicity in the methylene blue series via chromophore methylation. J Photochem Photobiol B Biol 1997; 40: 233-239.
13. 13 Wainwright M, Burrow SM, Guinot SGR, Phoenix DA, Waring J. Uptake and cell killing activities of a series of Victoria blue derivatives in a mouse mammary tumour cell line. Cytotechnology 1999; in press
14. 14 Wadwa K, Smith S, Oseroff AR. Cationic triarylmethane photosensitizers for photochemotherapy. SPIE 1988; 997: 154-160.
15. 15 Oster G. Dye binding to high polymers. J Polym Sci 1955; 36: 235-244.
16. 16 Cañete M, Villanueva A, Juarranz A. Uptake and photoeffectiveness of two thiazines in HeLa cells. Anti-Cancer Drug Design 1993; 8: 471-477.
17. 17 Fiedorowicz F, Galindo JR, Julliard M, Mannoni P, Chanon M. Efficient photodynamic action of Victoria blue BO against the human leukemic cell lines K-562 and TF-1. Photochem Photobiol 1993; 58: 356-361.
18. 18 Kessel D, Woodburn K. Selective photodynamic photoinactivation of a multidrug transporter by a cationic photosensitising agent. Br J Cancer 1995; 71: 306-310.
19. 19 Creagh TA, Gleeson M, Travis D, Grainger R, McDermott TED, Butler MR. Is there a role for in vivo methylene blue staining in the prediction of bladder tumour recurrence? Br J Urol 1995; 75: 477-479.
20. 20 Saul H. New light on cancer treatment. New Scientist 1993; 139, 17-20.
21. 21 Orth K, Ruck A, Stanescu A, Beger HG. Intraluminal treatment of inoperable oesophageal tumours by intraluminal photodynamic therapy with methylene blue. Lancet 1995; 345: 519-520.
22. 22 D'Halewin MA, Baert L. Long term results of whole bladder wall photodynamic therapy (PDT) for multifocal carcinoma in situ of the bladder. Urology 1995; 45: 763-767.
23. 23 Wainwright M. Non-porphyrin photosensitizers in biomedicine. Chem Soc Rev 1996; 25: 351-359.
24. 24 Wilson M. Photolysis of oral bacteria and its potential use in the treatment of caries and periodontal disease. J Appl Bacteriol 1993; 75: 299-306.
25. 25 Modica-Napolitano JS, Joyal JL, Ara G, Oseroff AR, Aprille JR. Mitochondrial toxicity of cationic photosensitizers for photochemotherapy. Cancer Res 1990; 50: 7876-7881.
26. 26 Darzinkiewicz Z, Carter SP. Photosensitizing effect of tricyclic heteroaromatic cationic dyes pyronin Y and toluidine blue O (tolonium chloride). Cancer Res 1988; 48: 1295-1299.
27. 27 Ruck A, Kollner T, Dietrich A, Strauss W, Schneckenburger H. Fluorescence formation during photodynamic therapy in the nuclueus of cells incubated with cationic and anionic water-soluble photosensitizers. J Photochem Photobiol B Biol 1992; 12: 403-412.
28. 28 Stockert JC, Juarranz A, Villanueva A, Cañete M. Photodynamic damage to HeLa cell microtubules induced by thiazine dyes. Cancer Chemother Pharmacol 1996; 39: 167-169.
29. 29 Yu DS, Chang SY, Ma CP. The effect of methylene blue-sensitized photodynamic treatment on bladder cancer cells: a further study on flow cytometric basis. J Urol 1993; 149: 1198-1204.
30. 30 Cox C. In vitro studies on the cellular mechanisms of resistance to cytotoxic compounds with special reference to multidrug resistance and cancer chemotherapy. PhD thesis, University of Central Lancashire 1993.
31. 31 Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colourimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-942.
32. 32 Skovsgaard T. Mechanisms of resistance to daunorubicin in resistant Ehrlich ascites tumour cells. Cancer Res 1978; 38: 1783-1791.
33. 33 Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukaemia cells in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967-1972.
34. 34 Dellinger M, Pressman BC, Calderon-Higginson C et al. Structural requirement of simple organic cations for recognition by multidrug-resistant cells. Cancer Res 1992; 52: 6385-6389.
35. 35 Goormatigh E, Ruysschaert JM. Anthracycline glycoside-membrane interactions. Biochim Biophys Acta 1984; 779: 271-288.
36. 36 de Wolf FA, Maliepaard M, van Dorsten F, Berguis I, Nicolay K, de Kruiff B. Comparable interaction of doxorubicin with various acidic phospholipids results in changes of lipid order and dynamics. Biochim Biophys Acta 1991; 1096: 67-80.
37. 37 de Wolf FA, Staffhorst RWHM, Smits HP, Onwezen MF, de Kruiff B. Role of anionic phospholipids in the interaction of doxorubicin and plasma membrane vesicles: drug binding and structural consequences in bacterial systems. Biochemistry 1993; 32: 6688-6695.